Tvardi Therapeutics initiates REVERTIPF trial in idiopathic pulmonary fibrosis

Tvardi Therapeutics, Inc., a clinical-stage biopharmaceutical company specializing in the development of STAT3 inhibitors, has reached a significant milestone by dosing the first patients in ... Read More